Year : 2025 | Volume : 12 | 02 | Page : –

Nikhil Mangesh Patil,

Suraj Vijay Magar,

Usama Kasam Rinde,

Pradhum Rajendra Biradar,

Sonali Dheeraj Parab,

Research Scholar, VP College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
Research Scholar, VP College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
Research Scholar, VP College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
Research Scholar, VP College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India
Research Scholar, VP College of Pharmacy Madkhol-Sawantwadi, Maharashtra, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_190193’);});Edit Abstract & Keyword

The traditional drug discovery process is often costly, time-consuming, and prone to high failure rates. The advent of Artificial Intelligence (AI) has revolutionized this field by significantly enhancing efficiency, reducing costs, and improving success rates. AI-driven approaches, including machine learning (ML), deep learning (DL), and natural language processing (NLP), have transformed key areas such as drug target identification, molecular screening, lead optimization, and clinical trial design. AI models can analyze large-scale biological and chemical data, predict molecular interactions, and optimize drug development pipelines. Applications like AI-driven virtual screening, AI-enabled gene editing, and predictive toxicology have demonstrated promising results in accelerating the discovery of novel therapeutics. Additionally, AI technologies such as Alpha Fold, IBM Watson, and DeepChem are proving instrumental in structure-based drug design and biomarker discovery. However, challenges such as data quality, ethical considerations, regulatory hurdles, and model interpretability remain key obstacles in AI-driven drug discovery. This review explores the latest advancements in AI-based pharmaceutical research, the impact of AI on various stages of drug development, and potential future directions in this rapidly evolving domain.

Keywords: Artificial Intelligence, drug discovery, investigational new drug, Investigational new drug, AI-based Disease Identification.

How to cite this article:
Nikhil Mangesh Patil, Suraj Vijay Magar, Usama Kasam Rinde, Pradhum Rajendra Biradar, Sonali Dheeraj Parab. AI-based Drug Discovery- Revolutionizing Pharmaceutical Research. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(02):-.

How to cite this URL:
Nikhil Mangesh Patil, Suraj Vijay Magar, Usama Kasam Rinde, Pradhum Rajendra Biradar, Sonali Dheeraj Parab. AI-based Drug Discovery- Revolutionizing Pharmaceutical Research. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 12(02):-. Available from: https://journals.stmjournals.com/rrjoddd/article=2025/view=0

Full Text PDF

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_190193’);});Edit

References

1. Wagner J, Dahlem AM, Hudson LD, Terry SF, Altman RB, et al. 2018. A dynamic map for learning, communicating, navigating and improving therapeutic development. Nat. Rev. Drug Discov. 17(2):150 2. Wagner JA, Dahlem AM, Hudson LD, Terry SF, Altman RB, et al. 2018. Application of a dynamic map for learning, communicating, navigating, and improving therapeutic development. Clin. Transl. Sci. 11(2):166-74
2. Tambuyzer E, Vandendriessche B, Austin CP, Brooks PJ, Larsson K, et al. 2020. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug Discov. 19(2):93-111 4. Zhu H. 2020. Big data and artificial intelligence modeling for drug discovery. Annu. Rev. Pharmacol. Toxicol. 60:573-89
3. Jayatunga MKP, Xie W, Ruder L, Schulze U, Meier C. 2022. AI in small-molecule drug discovery: a coming wave? Nat. Rev. Drug Discov. 21(3):175-76
4. Bentwich I. 2023. Pharma’s bio-AI revolution. Drug Discov. Today 28(5):103515
5. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, et al. 2019. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 18(6):463-77
6. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, et al. 2020. Rethinking drug design in the artificial intelligence era. Nat. Rev. Drug Discov. 19(5):353-64
7. Bender A, Cortés-Ciriano I. 2021. Artificial intelligence in drug discovery: What is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet. Drug Discov. Today 26(2):511-24
8. Bender A, Cortes-Ciriano I. 2021. Artificial intelligence in drug discovery: What is realistic, what are illusions? Part 2: a discussion of chemical and biological data. Drug Discov. Today 26(4):1040-52
9. Harris LA. 2021. Artificial intelligence: background, selected issues, and policy considerations. Rep. R46795, Congr. Res. Serv., Washington, DC. https://crsreports.congress.gov/product/pdf/R/R46795
10. Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today 2021, 26, 80–93. [CrossRef] [PubMed]
11. Xu, Y.; Liu, X.; Cao, X.; Huang, C.; Liu, E.; Qian, S.; Liu, X.; Wu, Y.; Dong, F.; Qiu, C.W.; et al. Artificial intelligence: A powerful paradigm for scientific research. Innovation 2021, 2, 100179. [CrossRef] [PubMed]
12. Zhuang, D.; Ibrahim, A.K. Deep learning for drug discovery: A study of identifying high efficacy drug compounds using a cascade transfer learning approach. Appl. Sci. 2021, 11, 7772. [CrossRef]
13. Pu, L.; Naderi, M.; Liu, T.; Wu, H.C.; Mukhopadhyay, S.; Brylinski, M. EToxPred: A machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacol. Toxicol. 2019, 20, 2. [CrossRef]
14. Rees, C. The Ethics of Artificial Intelligence. In IFIP Advances in Information and Communication Technology, 1st ed.; Chapman and Hall/CRC; CRC Press/Taylor & Francis Group: Boca Raton, FL, USA, 2020; Volume 555, pp. 55–69, ISBN 9781351251389.
15. Hinkson, I.V.; Madej, B.; Stahlberg, E.A. Accelerating therapeutics for opportunities in medicine: A paradigm shift in drug discovery. Front. Pharmacol. 2020, 11, 770. [CrossRef]
16. Zhou, Y.; Zhang, Y.; Lian, X.; Li, F.; Wang, C.; Zhu, F.; Qiu, Y.; Chen, Y. Therapeutic target database update 2022: Facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res. 2022, 50, D1398–D1407. [CrossRef]
17. Kana, O.; Brylinski, M. Elucidating the druggability of the human proteome with e findsite. J. Comput.-Aided Mol. Des. 2019, 33, 509–519. [CrossRef] [PubMed]
18. Finan, C.; Gaulton, A.; Kruger, F.A.; Lumbers, R.T.; Shah, T.; Engmann, J.; Galver, L.; Kelley, R.; Karlsson, A.; Santos, R. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 2017, 9, eaag1166. [CrossRef] [PubMed]
19. Schenone, M.; Danˇcík, V.; Wagner, B.K.; Clemons, P.A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 2013, 9, 232–240. [CrossRef]
20. Pun,F.W.; Ozerov, I.V.; Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacol. Sci. 2023, 44, 561–572. [CrossRef]
21. Pun,F.W.; Liu, B.H.M.; Long, X.; Leung, H.W.; Leung, G.H.D.; Mewborne, Q.T.; Gao, J.; Shneyderman, A.; Ozerov, I.V.; Wang, J. Identification of therapeutic targets for amyotrophic lateral sclerosis using PandaOmics–An AI-Enabled Biological Target Discovery Platform. Front. Aging Neurosci. 2022, 14, 638. [CrossRef]
22. Zhang,S.; Cooper-Knock, J.; Weimer, A.K.; Shi, M.; Moll, T.; Marshall, J.N.; Harvey, C.; Nezhad, H.G.; Franklin, J.; dos Santos Souza, C. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron 2022, 110, 992–1008.e1011. [CrossRef]
23. Zeng, X.; Zhu, S.; Lu, W.; Liu, Z.; Huang, J.; Zhou, Y.; Fang, J.; Huang, Y.; Guo, H.; Li, L. Target identification among known drugs by deep learning from heterogeneous networks. Chem. Sci. 2020, 11, 1775–1797. [CrossRef] [PubMed]
24. McCulloch,W.S.;Pitts, W.Alogicalcalculusofthe ideas immanentinnervousactivity. Bull. Math. Biophys. 1943, 5, 115–133. [CrossRef]
25. Baldi, A. Computational approaches for drug design and discovery: An overview. Syst. Rev. Pharm. 2010, 1, 99. [CrossRef]
26. Lavecchia, A.; Cerchia, C. In silico methods to address polypharmacology: Current status, applications and future perspectives. Drug Discov. Today 2016, 21, 288–298. [CrossRef]
27. Segall, M. Advances in multiparameter optimization methods for de novo drug design. Expert Opin. Drug Discov. 2014, 9, 803–817. [CrossRef] [PubMed]
28. M. Singer, C.S. Deutschman, C.W. Seymour, et al., The third international consensus definitions for sepsis and septic shock (Sepsis-3), Jama 315 (2016) 801 810.
29. M.P. Sendak, W. Ratliff, D. Sarro, et al., Real-world integration of a sepsis deep learning technology into routine clinical care: implementation study, JMIR medical informatics 8 (2020) e15182.
30. G. Husabø, I.L. Teig, J.C. Frich, et al., Promoting leadership and quality improvement through external inspections of management of sepsis in Norwegian hospitals: a focus group study, BMJ open 10 (2020) e041997.
31. A. Smith, Screening for drug discovery: the leading question, Nature 418 (2002) 453-455.
32. M. Butkiewicz, Y. Wang, S.H. Bryant, et al., High-throughput screening assay datasets from the pubchem database, Chemical informatics (Wilmington, Del.) 3 (2017).
33. F. Martin-Sanchez, K. Verspoor, Big data in medicine is driving big changes, Yearbook of medical informatics 23 (2014) 14-20.
34. K.P. Liao, T. Cai, G.K. Savova, et al., Development of phenotype algorithms using electronic medical records and incorporating natural language processing, bmj 350 (2015).
35. C. Isert, K. Atz, G. Schneider, Structure-based drug design with geometric deep learning, CurrOpinStructBiol 79 (2023) 102548.
36. J. Jin, D. Wang, G. Shi, et al., FFLOM: A Flow-Based Autoregressive Model for Fragment-to-Lead Optimization, J Med Chem 66 (2023) 10808-10823.
37. H. Li, L. Zou, J.A.H. Kowah, et al., A compact review of progress and prospects of deep learning in drug discovery, J Mol Model 29 (2023) 117.
38. J. Li, A. Fu, L. Zhang, An Overview of Scoring Functions Used for Protein Ligand Interactions in Molecular Docking, InterdiscipSci 11 (2019) 320-328.
39. S. Lu, X. He, D. Ni, et al., Allosteric Modulator Discovery: From Serendipity to Structure-Based Design, J Med Chem 62 (2019) 6405-6421.
40. D. Mucs, R.A. Bryce, The application of quantum mechanics in structure-based drug design, Expert Opin Drug Discov 8 (2013) 263-276.
41. D. Ni, Z. Chai, Y. Wang, et al., Along the allostery stream: Recent advances in computational methods for allosteric drug discovery, WIREs Computational Molecular Science 12 (2021).
42. Hay, M. et al. (2014) Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51
43. Harrer, S. et al. (2019) Artificial intelligence for clinical trial design. Trends Pharmacol. Sci. 40, 577–591
44. Fogel, D.B. (2018) Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun. 11, 156–164
45. Mak, K.-K. andPichika, M.R. (2019) Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today 24, 773–780
46. Hu F, Santagostino SF, Danilenko DM, Tseng M, Brumm J, et al. 2022. Assessment of skin toxicity in an in vitro reconstituted human epidermis model using deep learning. Am. J. Pathol. 192(4):687-700
47. Ramesh,A.; Kambhampati, C.; Monson, J.R.; Drew, P. Artificial intelligence in medicine. Ann. R. Coll. Surg. Engl. 2004, 86, 334. [CrossRef] [PubMed]
48. Miles, J.; Walker, A.J. The potential application of artificial intelligence in transport. In Proceedings of the IEE Proceedings Intelligent Transport Systems, Toronto, ON, Canada, 17–20 September 2006; pp. 183–198.
49. Mak,K.-K.; Pichika, M.R. Artificial intelligence in drug development: Present status and future prospects. Drug Discov. Today 2019, 24, 773–780. [CrossRef] [PubMed]
50. Duch,W.; Swaminathan, K.; Meller, J. Artificial intelligence approaches for rational drug design and discovery. Curr. Pharm. Des. 2007, 13, 1497–1508. [CrossRef] [PubMed]
51. Yang,Y.; Siau, K.L. A qualitative research on marketing and sales in the artificial intelligence age. In Proceedings of the Thirteenth Annual Midwest Association for Information Systems Conference (MWAIS 2018), St. Louis, MO, USA, 17–18 May 2018.
52. Wirtz, B.W.; Weyerer, J.C.; Geyer, C. Artificial intelligence and the public sector—Applications and challenges. Int. J. Public Adm. 2019, 42, 596–615. [CrossRef]
53. Sidey-Gibbons, J.A.; Sidey-Gibbons, C.J. Machine learning in medicine: A practical introduction. BMC Med. Res. Methodol. 2019, 19, 64. [CrossRef] [PubMed]
54. Carvalho, T.F.M.; Silva, J.C.F.; Calil, I.P.; Fontes, E.P.B.; Cerqueira, F.R. Rama: A machine learning approach for ribosomal protein prediction in plants. Sci. Rep. 2017, 7, 16273. [CrossRef] [PubMed]
55. Silva, J.C.F.; Teixeira, R.M.; Silva, F.F.; Brommonschenkel, S.H.; Fontes, E.P. Machine learning approaches and their current application in plant molecular biology: A systematic review. Plant Sci. 2019, 284, 37–47. [CrossRef] [PubMed]
56. Manne,R.Machine learning techniques in drug discovery and development. Int. J. Appl. Res. 2021, 7, 21–28. [CrossRef]
57. Polydoros, A.S.; Nalpantidis, L. Survey of model-based reinforcement learning: Applications on robotics. J. Intell. Robot. Syst. 2017, 86, 153–173. [CrossRef]
58. Kubat, M.; Kubat, J. An Introduction to Machine Learning; Springer: Berlin/Heidelberg, Germany, 2017; Volume 2.
59. Birhane, A.; Kasirzadeh, A.; Leslie, D.; Wachter, S. Science in the age of large language models. Nat. Rev. Phys. 2023, 5, 277–280. [CrossRef]
60. R. Qureshi, M. Irfan, T. M. Gondal, S. Khan, J. Wu, M. U. Hadi, J. Heymach, X. Le, H. Yan, T. Alam, Heliyon 2023, 9, https://doi.org/10. 1016/J.HELIYON.2023.E17575.
61. D. Paul, G. Sanap, S. Shenoy, D. Kalyane, K. Kalia, R. K. Tekade, Drug Discov Today 2021, 26, 80–93. https://doi.org/10.1016/J.DRUDIS.2020. 10.010.
62. J. C. Pereira, E. R. Caffarena, C. N. Dos Santos, J ChemInf Model 2016, 56, 2495–2506. https://doi.org/10.1021/ACS.JCIM.6B00355/ASSET/IM AGES/MEDIUM/CI-2016-003556 0008.GIF.
63. H. C. S. Chan, H. Shan, T. Dahoun, H. Vogel, S. Yuan, Trends PharmacolSci 2019, 40, 592–604. https://doi.org/10.1016/J.TIPS.2019.06.004.
64. H. Zhu, Annu Rev PharmacolToxicol 2020, 60, 573–589. https://doi.org/ 10.1146/ANNUREV-PHARMTOX-010919-023324/CITE/REFWORKS.
65. N. Brown, In Silico Medicinal Chemistry: Computational Methods to Support Drug Design, The Royal Society of Chemistry, Cambridge, 2015. https://doi.org/10.1039/9781782622604.
66. H. L. Ciallella, H. Zhu, Chem Res Toxicol 2019, 32, 536–547. https://doi. org/10.1021/ACS.CHEMRESTOX.8B00393/ASSET/IMAGES/MEDIUM/TX 2018-00393B_0004.GIF.
67. Y. Zhou, Y. Zhang, X. Lian, F. Li, C. Wang, F. Zhu, Y. Qiu, Y. Chen, Nucleic Acids Res 2022, 50, D1398–D1407. https://doi.org/10.1093/NAR/ GKAB953.
68. S. R. Khan, D. Al Rijjal, A. Piro, M. B. Wheeler, Drug Discov Today 2021, 26, 982–992. https://doi.org/10.1016/J.DRUDIS.2021.01.008
69. P. C. Agu, C. N. Obulose, Drug Dev Res 2024, 85, e22159. https://doi. org/10.1002/DDR.22159.
70. Z. Yang, X. Zeng, Y. Zhao, R. Chen, Signal Transduction and Targeted Therapy 2023 8, 1–14. https://doi.org/10.1038/s41392-023-01381-z.
71. AlphaFold2 @ CASP14: “It feels like one’s child has left home.” «Some Thoughts on a Mysterious Universe, (n.d.). https://moalquraishi.word-press.com/2020/12/08/alphafold2-casp14-it-feels-like-ones-child-has left-home/ (accessed April 8, 2024)
72. P. Agrawal, Artificial Intelligence in Drug Discovery and Development 2018, https://doi.org/10.4172/2329-6887.1000e173
73. B. Ramsundar, P. Eastman, P. Walters, V. Pande, K. Leswing, Z. Wu, Deep Learning for the Life Sciences: Applying Deep Learning to Genomics, Microscopy, Drug Discovery, and More, O’Reilly Media, Inc, 2019.
74. X. Li, Y. Sun, Z. Zhou, J. Li, S. Liu, L. Chen, Y. Shi, M. Wang, Z. Zhu, G. Wang, Q. Lu, Advanced Science 2024, 2308970. https://doi.org/10.1002/ ADVS.202308970.
75. R. R. Narayanan, N. Durga, S. Nagalakshmi, Indian Journal of Pharma ceutical Education and Research 2022, 56, s387–s397. https://doi.org/ 10.5530/ijper.56.3s.146.
76. P. P. Parvatikar, S. Patil, K. Khaparkhuntikar, S. Patil, P. K. Singh, R. Sahana, R. V. Kulkarni, A. V. Raghu, Antiviral Res 2023, 220, 105740. https://doi.org/10.1016/J.ANTIVIRAL.2023.105740.
77. C. Stork, J. Wagner, N. O. Friedrich, C. de Bruyn Kops, M. Šícho, J. Kirchmair, ChemMedChem 2018, 13, 564–571. https://doi.org/10.1002/ CMDC.201700673.
78. L. L. G. Ferreira, A. D. Andricopulo, Drug Discov Today 2019, 24, 1157 1165. https://doi.org/10.1016/J.DRUDIS.2019.03.015.
79. Zhou, Y., et al. (2019). Deep learning for drug discovery: A review. Drug Discovery Today, 24(4), 770-783
80. Yue, W., et al. (2020). AI and drug discovery: A review of recent developments and applications. Computational Biology and Chemistry, 84, 107188.
81. Sanchez-Lengeling, B., et al. (2018). Inverse design of molecular compounds through deep generative models. Science, 359(6379), 1142-1147.
82. Chen, H., et al. (2020). Drug discovery through deep learning: A systematic review. Journal of Chemical Information and Modeling, 60(7), 3263-3274.
83. Roth, S., et al. (2016). Computational models for predicting toxicology: From basic research to preclinical trials. Nature Reviews Drug Discovery, 15(6), 325-338.
84. Zhao, L., et al. (2020). Machine learning in biomarker discovery: From diagnostic biomarkers to therapeutic biomarkers. Frontiers in Pharmacology, 11, 497.
85. Ochoa, D., et al. (2019). Artificial intelligence and patient stratification in clinical trials. Clinical Pharmacology and Therapeutics, 105(5), 1085-1094.
86. Moses, L., et al. (2019). The role of artificial intelligence in clinical trial design and optimization. JAMA Network Open, 2(8), e1910317.
87. Liu, Q., et al. (2021). Pharmacovigilance and artificial intelligence: Opportunities and challenges. Pharmacological Research, 168, 105623.
88. Vamathevan, J.; Clark, D.; Czodrowski, P.; Dunham, I.; Ferran, E.; Lee, G.; Li, B.; Madabhushi, A.; Shah, P.; Spitzer, M.; et al. Applications of machine learning in drug discovery and development. Nat. Rev. Drug Discov. 2019, 18, 463–477. [CrossRef] [PubMed]
89. Tsuji, S.; Hase, T.; Yachie-Kinoshita, A.; Nishino, T.; Ghosh, S.; Kikuchi, M.; Shimokawa, K.; Aburatani, H.; Kitano, H.; Tanaka, H. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer’s disease. Alzheimer Res. Ther. 2021, 13, 92. [CrossRef]
90. Gómez-Bombarelli, R.; Wei, J.N.; Duvenaud, D.; Hernández-Lobato, J.M.; Sánchez-Lengeling, B.; Sheberla, D.; Aguilera Iparraguirre, J.; Hirzel, T.D.; Adams, R.P.; Aspuru-Guzik, A. Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules. ACS Central Sci. 2018, 4, 268–276. [CrossRef]
91. Basu, T.; Engel-Wolf, S.; Menzer, O. The ethics of machine learning in medical sciences: Where do we stand today? Indian J. Dermatol. 2020, 65, 358–364. [CrossRef] [PubMed]
92. Kleinberg, J. Inherent Trade-Offs in Algorithmic Fairness. In Proceedings of the Abstracts of the 2018 ACM International Conference on Measurement and Modeling of Computer Systems, Irvine, CA, USA, 18–22 June 2018; Association for Computing Machinery (ACM): New York, NY, USA, 2018; p. 40.
93. Silvia, H.; Carr, N. When Worlds Collide: Protecting Physical World Interests Against Virtual World Malfeasance. Michigan Technol. Law Rev. 2020, 26, 279. [CrossRef]
94. Shimao, H.; Khern-am-nuai, W.; Kannan, K.; Cohen, M.C. Strategic Best Response Fairness in Fair Machine Learning. In Proceedings of the 2022 AAAI/ACM Conference on AI, Ethics, and Society, New York, NY, USA, 7–9 February 2022; Association for Computing Machinery (ACM): New York, NY, USA, 2022; p. 664.
95. Kusam,L.; Mayank, D.; Nishanth, K.N. Data Augmentation Using Generative Adversarial Network. In Proceedings of the 2nd International Conference on Advanced Computing and Software Engineering (ICACSE) 2019, Sultanpur, India, 8 February 2019. [CrossRef]
96. Lamberti, M.J. et al. (2019) A study on the application and use of artificial intelligence to support drug development. Clin. Ther. 41, 1414–1426
97. NguengangWakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. (2020) 28:165–73. 10.1038/s41431-019-0508-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

Ahead of Print Subscription Original Research

Research & Reviews: A Journal of Drug Design & Discovery

ISSN: 2349-9036

Volume	12
	02
Received	17/04/2025
Accepted	21/04/2025
Published	23/05/2025
Publication Time	36 Days

100

[first_name] [last_name]

PlumX Metrics

Initiatives

Legal Information

Contact Us

STM Journals
An imprint of Consortium E-learning network Pvt. Ltd.
A-118, 1st Floor, Sector-63, Noida, U.P. India, Pin-201301
(Tel) (+91) 0120- 4781 200
(Mob) (+91) 9810078958, +919667725932
[email protected]

Join Us

Submit Manuscript

Submit Topics

WEBSITE DISCLAIMER

Last updated: 2022-06-15

The information provided by STM Journals (“Company”, “we”, “our”, “us”) on https://journals.stmjournals.com/ (the “Site”) is for general informational purposes only. All information on the Site is provided in good faith, however, we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information on the Site.

UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE SITE OR RELIANCE ON ANY INFORMATION PROVIDED ON THE SITE. YOUR USE OF THE SITE AND YOUR RELIANCE ON ANY INFORMATION ON THE SITE IS SOLELY AT YOUR OWN RISK.

EXTERNAL LINKS DISCLAIMER

The Site may contain (or you may be sent through the Site) links to other websites or content belonging to or originating from third parties or links to websites and features. Such external links are not investigated, monitored, or checked for accuracy, adequacy, validity, reliability, availability, or completeness by us.

WE DO NOT WARRANT, ENDORSE, GUARANTEE, OR ASSUME RESPONSIBILITY FOR THE ACCURACY OR RELIABILITY OF ANY INFORMATION OFFERED BY THIRD-PARTY WEBSITES LINKED THROUGH THE SITE OR ANY WEBSITE OR FEATURE LINKED IN ANY BANNER OR OTHER ADVERTISING. WE WILL NOT BE A PARTY TO OR IN ANY WAY BE RESPONSIBLE FOR MONITORING ANY TRANSACTION BETWEEN YOU AND THIRD-PARTY PROVIDERS OF PRODUCTS OR SERVICES.

PROFESSIONAL DISCLAIMER

The Site can not and does not contain medical advice. The information is provided for general informational and educational purposes only and is not a substitute for professional medical advice. Accordingly, before taking any actions based on such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical advice.

Content published on https://journals.stmjournals.com/ is intended to be used and must be used for informational purposes only. It is very important to do your analysis before making any decision based on your circumstances. You should take independent medical advice from a professional or independently research and verify any information that you find on our Website and wish to rely upon.

THE USE OR RELIANCE OF ANY INFORMATION CONTAINED ON THIS SITE IS SOLELY AT YOUR OWN RISK.

AFFILIATES DISCLAIMER

The Site may contain links to affiliate websites, and we may receive an affiliate commission for any purchases or actions made by you on the affiliate websites using such links.

TESTIMONIALS DISCLAIMER

The Site may contain testimonials by users of our products and/or services. These testimonials reflect the real-life experiences and opinions of such users. However, the experiences are personal to those particular users, and may not necessarily be representative of all users of our products and/or services. We do not claim, and you should not assume that all users will have the same experiences.

YOUR RESULTS MAY VARY.

The testimonials on the Site are submitted in various forms such as text, audio, and/or video, and are reviewed by us before being posted. They appear on the Site verbatim as given by the users, except for the correction of grammar or typing errors. Some testimonials may have been shortened for the sake of brevity, where the full testimonial contained extraneous information not relevant to the general public.

The views and opinions contained in the testimonials belong solely to the individual user and do not reflect our views and opinions.

ERRORS AND OMISSIONS DISCLAIMER

While we have made every attempt to ensure that the information contained in this site has been obtained from reliable sources, STM Journals is not responsible for any errors or omissions or the results obtained from the use of this information. All information on this site is provided “as is”, with no guarantee of completeness, accuracy, timeliness, or of the results obtained from the use of this information, and without warranty of any kind, express or implied, including, but not limited to warranties of performance, merchantability, and fitness for a particular purpose.

In no event will STM Journals, its related partnerships or corporations, or the partners, agents, or employees thereof be liable to you or anyone else for any decision made or action taken in reliance on the information in this Site or for any consequential, special or similar damages, even if advised of the possibility of such damages.

GUEST CONTRIBUTORS DISCLAIMER

This Site may include content from guest contributors and any views or opinions expressed in such posts are personal and do not represent those of STM Journals or any of its staff or affiliates unless explicitly stated.

LOGOS AND TRADEMARKS DISCLAIMER

All logos and trademarks of third parties referenced on https://journals.stmjournals.com/ are the trademarks and logos of their respective owners. Any inclusion of such trademarks or logos does not imply or constitute any approval, endorsement, or sponsorship of STM Journals by such owners.

Use of AI Tools in Blog Content

Some of the blog posts published on this website are created with the assistance of Artificial Intelligence (AI) tools. While efforts are made to review and edit the content for accuracy and appropriateness, there may still be instances where unintended, unnecessary, or unverified information or claims appear.Readers are advised to use their discretion while interpreting the content. The primary purpose of using AI-generated content is to provide our audience with the most recent, diverse, and wide-ranging information on various topics. The content is intended to inform and engage, not to mislead.All external links included in the blogs are intended to guide users to real and authentic workshops, programs, or resources. The information presented through those links is curated and verified to the best of our knowledge.This disclaimer is meant to inform visitors about the use of AI in content creation, acknowledge potential limitations in content accuracy, and encourage informed and responsible reading.

CONTACT US

Should you have any feedback, comments, requests for technical support, or other inquiries, please contact us by email: [email protected].